A single decision out of Washington has sent a chill through the entire mRNA space. The U.S. Department of Health and Human Services terminated a roughly $590 million contract with Moderna to develop a bird flu vaccine, abruptly underscoring how quickly government pandemic priorities can shift. BioNTech was not directly affected, but the move reinforces a broader message: public funding for mRNA platforms is no longer a sure bet, and the sector’s reliability as a recipient of political goodwill has taken a hit.
That backdrop only amplifies the pressure already weighing on BioNTech, which ended last week at €76.65, down 6.92% over seven days and 20.36% lower than a year ago. The stock now sits nearly 30% below its 52-week high of €105.80, and the nearest support — the March low of €68.35 — is uncomfortably close. The RSI of 40.4 suggests selling pressure is building, though the shares have not yet tipped into technically oversold territory.
The company’s first-quarter results for 2026 painted a stark picture of the revenue transition. Sales fell to €118.1 million from €182.8 million in the prior-year period, while the net loss widened to €531.9 million. The Covid vaccine franchise is fading fast, and the oncology pipeline has yet to generate meaningful commercial revenue. Management still expects full-year revenue of €2.0 billion to €2.3 billion, chiefly from licensing and partnership income, and has a €1 billion share buyback program on the table. With roughly €16.8 billion in liquidity, the cash cushion is more than adequate — but a strong balance sheet alone does not drive a stock higher.
On the regulatory front, the clouds are thickening. The Consolidated Appropriations Act of 2026 and ongoing price negotiations by the U.S. Centers for Medicare & Medicaid Services (CMS) are reshaping margin expectations for innovative drug developers. The government is also examining “most-favored-nation” pricing models, which could impose mandatory discounts and government-negotiated price caps on costly medicines. If implemented, these measures would weigh on profitability across the sector for years.
Amid those headwinds, the ASCO cancer conference in late May gave BioNTech a chance to showcase its oncology credentials. The company presented late-stage data for its candidates pumitamig (in partnership with Bristol Myers Squibb) and gotistobart, along with a broader pipeline update that included antibody-drug conjugates, immunomodulators, and combination therapies. The science drew attention, but the market remained unmoved. The closing price suggests investors are still demanding proof of commercial viability, not just scientific promise.
Should investors sell immediately? Or is it worth buying BioNTech?
The technical picture underscores that skepticism. At €76.65, BioNTech is trading 5.45% below its 50-day moving average of €81.07 and 10.82% below the 200-day line of €85.95. The 100-day average sits at €85.39 and the 200-day at €85.95, forming a compact resistance band. The annualized 30-day volatility of 27.50% is a reminder that this remains an event-driven stock, where each clinical announcement can either reinforce or undermine the narrative.
A separate piece of news during the week offered a glimpse of the old story still alive: Pfizer and BioNTech announced that the European Commission had approved a pediatric update for their Covid vaccine, which the companies said would simplify vaccination practice for families and healthcare professionals. In earlier times, that would have moved the share price. Today it registers as a maintenance item, not a catalyst.
The valuation gap is telling. BioNTech’s market capitalization stands at €19.62 billion, while the consensus analyst price target is €106.32 — implying theoretical upside of 38.7%. That chasm captures the company’s predicament: models still embed considerable value, but the screen reflects a market that pays for validated next steps, not for optionality. The transition from a vaccine-revenue story to an oncology-platform story is not yet priced in, because the evidence required to close that gap has not fully arrived.
Management has framed 2026 as a year of preparation: adapting Covid vaccines, lowering vaccine revenue, consolidating production, and shifting capital allocation toward oncology. The old pillar is still standing, but it no longer carries the market’s imagination. The next revaluation will depend on clinical milestones that measurably shrink the distance between pipeline and market — and on whether Washington’s pricing reforms ultimately constrain that path.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 6 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 6.
BioNTech: Buy or sell? Read more here...
